Identifying driver genetic mutations and PDL1 levels through comprehensive genetic testing in early and advanced lung cancer forms the basis of an innovative treatment plan. Smart pill therapies to be used in patients with driver mutations can provide much more effective and comfortable treatments compared to standard chemotherapy. In driver mutation-negative patients, immunotherapy alone (activating the immune system) or in combination with chemotherapy is determined according to the PDL1 level. For this reason, international guidelines also recommend comprehensive genetic testing and PDL1 testing for patients diagnosed with lung cancer at category 1 level (the highest level of evidence).